Item 0 1:
Topic: SARS vaccine development: production and immunology of spike protein.
Expression of SARS virus in Pichia pastoris.
Funding amount: $50,000
Date: 2003-2005
Item 02:
Project name: A phase I randomized single-center study to compare the safety and immune dose of PFCP-2.9 recombination vaccines adjuvant with Montani de ISA 720.
Funding amount: 8 1300 USD.
Date: 2003-2004
Item 03:
Project name: Construction and immunology of Malaysia vacuum containing PFCP-2.9 and pre-evolutionary antigen.
Funding amount: 1 1. 1 ten thousand dollars.
Date: 2002-2006
Item 04:
Key words: Optimized synthesis of paramyosin (SJ-97) codon and its expression in Pichia pastoris.
Funding amount: $35,000
Date: 2002-2003
Item 05:
Project name: Pre-clinical study on the consistency of C-terminal chimeric proteins of Plasmodium falciparum ama- 1 and MSP 119 kDa.
Funding amount: USD 654.38+USD 200,000.
Date: 2000-2003
Item 06:
Subjects' names: Two Malaysian antigens, complete MSP 1 and AMA-1/MSP1-19 chimeric proteins, were examined as vacuum candidates.
Funding amount: 123900 USD.
Date: 1999-2002
Item 07:
Title: Production and immunology of major surface proteins of plasmodium falciparum merozoite in Pichia pastoris.
Amount of funds: $65,000
Date: 1998-2000
Item 08:
Title: Synthesis and expression of chimera of malaria vacuum candidate gene.
Funding amount: 60,300 USD.
Date: 1998-2000
Item 09:
Project name: Expression and immunology of Plasmodium falciparum MSP 1/GP 190 in Salmonella typhi vacuum strain.
Funding amount: US$ 62,500.
Start date: 1996- 1999.
Swedish karolinska institutet Cooperation Fund:
Development and evaluation of malaria vacuum in primate model.
Funding amount: 600,000 SEK (of which 224,000 SEK will be transferred to our office).
Date: 2004-2006
2. Domestic fund projects (total funds received: 8,654.38+800,000 yuan)
Project name: Identification and application of protective CD4+ T cell epitopes in red blood cell phase of malaria.
Source of funds: National Natural Science Foundation of China
Funding amount: 260,000 yuan
Date: 2007-2009
Project Name: Study on Malaria Erythrocyte Vaccine and Its Immune Protection Mechanism
Subject number: 06XD 1402
Source of funds: Shanghai Excellent Academic Leaders Program.
Funding amount: 250,000 yuan
Start date: September 2006 to August 2008.
Project name:
Source of funds: the 11th Five-Year Plan of the army.
Funding amount: 400,000 yuan
Date: 2006
Fund category: funds that host international conferences.
Source of funds: National Natural Science Foundation of China
Funding amount: 30,000 RMB.
Date: 2005
Fund category: funds that host international conferences.
Source of funds: Shanghai Science and Technology Commission (Magnolia Fund)
Funding amount: 20,000 RMB.
Date: 2005
Title: Clinical study of recombinant malaria vaccine.
Fund category: major national science and technology projects
Funding amount: 2.5 million RMB.
Date: 2003-2005
Title: Pilot and clinical study of recombinant malaria vaccine.
Fund category: major scientific and technological projects in Shanghai
Funding amount:100000 RMB.
Date: 2003-2006
Title: Study on Immune Protection Mechanism of Recombinant Malaria Vaccine PfCP-2.9
Fund category: key projects of the National Natural Science Foundation of China
Funding amount: RMB 6,543,800+400,000.
Date: 2005-2009
Topic: Malaria-related proteins and their prevention and treatment.
Fund category: National Science Fund for Distinguished Young Scholars
Funding amount:100000 RMB.
Date: 2002-2006
Title: Pilot and clinical study of recombinant malaria vaccine.
Fund category: National 863 Program Project
Funding amount: 2.07 million yuan (responsible for three sub-projects)
Date: 200 1-2003
Study on recombinant malaria vaccine
Fund category: National 863 Program Project
Funding amount: 400,000 RMB.
Date: 1999-2000
Topic: development of SARS subunit vaccine
Fund category: Shanghai SARS Special Fund
Funding amount: 400,000 RMB.
Date: 2003-2004
Subject: Pre-clinical study of recombinant malaria vaccine.
Fund category: mandatory military projects
Funding amount: 500,000 RMB.
Date: 200 1-2003
Topic: Pre-clinical study of recombinant malaria vaccine.
Fund category: Shanghai New Drug Fund
Funding amount: 500,000 RMB.
Date: 200 1-2003
Topic: Establishing MSP 1 transgenic animal model by gene targeting technology.
Fund category: National Natural Science Foundation Project
Funding amount: 654.38 yuan+900,000 yuan.
Date: 2002-2004
Development of recombinant malaria vaccine
Fund category: joint school research projects
Funding amount: 500,000 RMB.
Start date: 2000-2002
Expression of MSP 1 gene of tetracycline-induced falciparum malaria in human typhoid vaccine strain.
Fund category: National Natural Science Foundation Project
Funding amount: 654.38 yuan+200,000 yuan.
Date: 1997-2000
Verb (abbreviation for verb) patents and papers
Patent for invention applied for and authorized
(1). Name: fusion antigen of plasmodium and its preparation method and application.
Inventor: Pan
Type: invention patent
Authorization time: 165438+20041October 24th.
Country: China
(2) Name: plasmodium fusion protein: preparation and use.
Inventor: Pan
Type: invention patent
Authorized country: United States
Patent number: USA: US 10/467 198.
Date of authorization: 2006
(3) Name: Plasmodium Fusion Protein: Preparation and Application
Inventor: Pan
Type: invention patent
Authorized country: EU
Patent number:
Date of authorization: 2006
(4) Name: plasmodium fusion protein: preparation and use.
Inventor: Pan
Type: invention patent
Authorized country: Australia
Patent number:
Date of authorization: 2007
(5) Name: Recombination method for preparing complete malaria antigen gp 190/MSP 1.
Inventors: H. Bouillard, R. Toler, W. Pan.
Type: invention patent
Authorized country: China.
Date of authorization: May 5, 2004
(6) Name: Recombination process for preparing complete malaria antigen, GP 190/MSP 1.
Inventors: H. Bouillard, R. Toler, W. Pan.
Type: invention patent
Authorized country: Australia
Authorization date: 2006 54 38+0 04 654 38+09.
(7) Name: Recombination process for preparing complete malaria antigen, GP 190/MSP 1.
Inventors: H. Bouillard, R. Toler, W. Pan.
Type: invention patent
Authorized country: United States
Date of authorization: August 25, 2005
(8) Name: Recombinant Plasmodium falciparum hypoxanthine-guanine phosphoribosyltransferase, its preparation method and application.
Inventors: Zhang Dongmei and Pan.
Type: invention patent
Application date: July 2005 18.
Application number: 200510027811.1.
(9) Name: Recombinant Plasmodium falciparum 175kD red blood cell binding antigen functional region protein, its preparation method and application.
Inventor: Pan,
Type: invention patent
Date of application: June 29, 2005
Application number: 2005 100733.438+0.
2. Industrialization of scientific research achievements and its transfer
The genetically engineered malaria vaccine has been transferred to Shanghai Wanxing Biopharmaceutical Co., Ltd. ..
3. Representative document (*: correspondent)
, Li Qu, Pan,, Construction and evaluation of multi-level combined malaria vaccine, vaccine 25 (2007) 212–2119,
Kirsten Moore, Arnold Cheney. Ulf Reback. , Osamu Kaneko4, Sandra Nilsson, Gerhard Winter, Malin Haegstrom, Wei Qing Pan, Klavs Berzins6, Matz Vallgren, Chen Qijun *, a new DBL domain of Plasmodium falciparum 332 molecule may be related to erythrocyte adhesion, PLoS ONE, 2007, 5:477.
Langermans Jahensmann m van Gijlswiik m Zhang d pan w giersing Bkloke e dubovsk f wittes j Thomas aw, Montanide ISA 720 Pre-clinical evaluation of chimeric malaria vaccine candidates: immunogenicity and safety of rhesus monkeys.
Hmm. Vaccine. September 2006 to 10; 2(5):222-6.
D. Zhang, Pan Weiqun, Qian, Du Keming, Shen Lihong, et al. Study on immunogenicity and vaccine efficacy of recombinant Schistosoma japonicum paramyosin fragment in mice. Parasitic immunology 2006,28 (3): 77-84
And Pan *(2005) evaluated the merozoite protein of Plasmodium falciparum expressed by three Pichia pastoris as a combined vaccine against blood parasites. Infection and Immunity, 73( 10):6530-6536
Balu WR, Arevalo Herrera M, Carrucci D, Richie TL, Corradin G, Digges C, Druai P, Gilsin BK, Sol A, Hepner DG, Kester G, Ranar De, Leon J, Hill AV, Pan. Recent progress in clinical development of candidate malaria vaccines. I am too fat. Aug7 1:239-47
Pan *, Huang Daqing, Li Qu,,, Qian Feng, the fusion of two candidate malaria vaccines improved the product yield, immunogenicity and antibody-mediated growth inhibition of ectoparasites. Journal of immunology 2004,172: 6167-6174.
Pan (with) (2002). Construction of tetR-integrated Salmonella typhimurium CVD908 strain, which strictly controls the expression of major merozoite surface proteins of Plasmodium falciparum and is used for human vaccine production, infection and immunity, 70(4):2029.
Wei Qing Pan, Elie Dabeta Lavaute, Ralph Toler, Lena Frank, Raphael Morsbach, ivanna TourBacova and Herman Boujude (1999), vaccine candidate from Plasmodium falciparum MSP- 1: The redesigned 49 17 bp polynucleotide makes.
Wei Qing Pan, Ralph Thor and Herman Bujad (1995), Direct Rapid Sequencing Strategy of Plasmodium falciparum Antigen Gene gp 190/MSA 1, Molecular and Biochemical Parasitology, 73:24 1
Petra Burghaus, Peter Gerold, Wei Qing Pan, Ralph Schwarz, Klaus Lingelbach, Hermann Bujard( 1999) Analysis of plasmodium merozoite surface protein-1, molecular and biochemical parasitology,104:/kloc-.
Qian Feng, Nie Benyong, Ping, Xing and Qing. Sequence variation of apical membrane antigen 1 in the endemic area of Plasmodium falciparum in China and recognition of naturally acquired antibodies. China Journal of Medicine (Revised Edition) 2004.
Pan, Deng Hailin, Lu Deru (1993), Study on antigenic variation of Plasmodium falciparum P 190 in Hainan Province, China Science, 23: 1070.
Pan *, Lu Deru (2002). Recombinant merozoite surface protein 1 specific antibody effectively inhibits the growth of Plasmodium falciparum in vitro, Journal of Biochemistry and Biophysics, 34(3)(SCI)
Qian Feng, Pan * (2001). Cre/loxP-mediated deletion of inserted genes in salmonella typhi chromosome, progress in biochemistry and biophysics, 28,732 (SCI journal)
Pan *, Qu Li (2003). Effect of N-terminal deletion of 9 amino acids on immunogenicity of fusion antigen of falciparum malaria, Journal of Biochemistry and Biophysics, 35(4):345-349(SCI),
5. Publication of works:
(1) Pan and Tang, molecular parasitology, Shanghai Science and Technology Press, 2004.
Won the second prize of excellent science and technology books in the 18th East China Science and Technology Publishing House.
(2) Research and Application of Parasite Biology, edited by Pan, Chemical Industry Press, 2007.
6. Reward:
2006: Selected as an outstanding academic leader in Shanghai.
2004: Silver Star Medal for Science and Technology of PLA General Logistics Department
2003: President Award of the Second Military Medical University
2003: Enjoy the post allowance of the first batch of outstanding military professionals.
2002: winner of the National Science Fund for Distinguished Young Scholars.
Won the military academy silver medal in 2002.
200 1, awarded the third class.
In 2000, he won the Meiji Dairy Life Science Award.
In 2000, he won the Excellent Scientific Research Award of Jin Run Award Fund.
Sixth, academic exchanges.
Participate in WHO academic conferences as temporary consultant of WHO;
June 2003: Attended the World Health Organization Global SARS Conference.
Venue: Kuala Lumpur, Malaysia
June, 2003: 5438+065438+ 10: Attended the World Health Organization's global expert consultation on SARS vaccine.
Venue: Geneva, Switzerland
June 5-38, 2003+10: Attended the World Health Organization meeting on schistosomiasis vaccine.
Venue: Manila, Philippines
June 2003: World Health Organization conference on vaccines and new adjuvants.
Venue: Annes, France
June 2003: World Health Organization Global Vaccine Conference
Venue: Seoul, Korea
June 5-38, 2002+10: Attended the World Health Organization meeting on vaccines and new adjuvants.
Venue: Annes, France
March 2002: Attended the World Health Organization Global Vaccine Conference.
Venue: Geneva, Switzerland
June 1999: Attended the World Health Organization conference on malaria and schistosomiasis vaccines.
Venue: Manila, Philippines
1March, 998: Special Report: Research Progress of Candidate Antigen MSP 1 for Malaria Vaccine.
Venue: World Health Organization Headquarters, Geneva, Switzerland
Report of academic conference (international conference part)
International protozoan congress
Report Type: Keynote Speaker
Report title: Research and development of combined vacuum against plasmodium.
Location: China.
2005 10: 2005 international congress on parasitology and vector biology
Report Type: Keynote Speaker
Report title: Research and development of combined vacuum against plasmodium.
Location: China.
February 2000: Conference on Molecular Biology of Malaria
Report Type: Invited Speaker
Title of the report: Two malaria antigens, MSP 1 and Plasmodium falciparum chimeric protein, were tested as vaccines.
Location: Australia
June 5-38, 2002+10: World Health Organization meeting on new adjuvants.
Report Type: Invitation Report
Topic: Immunogenicity of Plasmodium falciparum chimeric protein 2 regulated by montani de ISA 720 in rabbits and monkeys.
Venue: Annes, France
June 5-38, 2003+10: World Health Organization meeting on schistosomiasis vaccine.
Report Type: Invitation Report
Report Title: Examples of Vacuum Research and Development in Malaysia
Venue: Manila, Philippines
June 2003: World Health Organization conference on vaccines and new adjuvants.
Report Type: Invitation Report
Report title: Montana de ISA 720 combined with malaria antigen adjuvant.
Venue: Annes, France
June 5438+February 2000: MSP 1 Vaccine Conference of Bill Gates Foundation.
Report title: Production of MSP 1-42 and Plasmodium falciparum chimeric protein in Pichia pastoris.
Venue: Washington, USA
June 2006 5438+0: 1 1 Asia-Pacific Military Medical Conference.
Report Type: Sub-topic Report
Report topic: malaria vacuum development: mass production and preclinical study of Plasmodium falciparum chimeric protein as vacuum candidate.
Venue: New Zealand
3. Special report (foreign part)
June 5438+February 2000: Report Title: Detection of Plasmodium falciparum chimeric protein.
As a candidate vaccine
Report location: NIH, USA
Coconut University of America;
New York University
1March, 998: report title: synthesis and expression of complete merozoite surface protein.
Plasmodium falciparum
Report location: Geneva, Switzerland
September 2003: Report Title: PFCP-2.9 Vaccine Candidate: Research and Development.
Location: karolinska institutet, Sweden
February 2004: Report Title: PFCP-2.9 Vaccine Candidate: Research and Development.
Report location: Centers for Disease Control and Prevention, USA
June 5438, 2006+10: Report title: Discovery of malaria vaccine.
Venue: Nagasaki University, Japan
Hosting or undertaking international conferences
2005123-26 October: 2005 International Conference on Parasitology and Vector Biology (sponsored)
Chairman: Pan Weiqing, NIH.
1998 65438+February 7-10: World Health Organization International Conference on Vaccine Research (sponsored)
Meeting place: Shanghai; Time: 4 days
The latest issue of The Lancet, the top international academic journal Infectious Diseases in The Lancet, published the latest scientific research results of Pan's team online in the form of papers, and distributed the comments of Professor Clive Schiff from Pueblo School of Health, Johns Hopkins University, USA: "The research team screened sensitive diagnostic molecules from the whole genome, which will greatly improve the detection technology of schistosomiasis, thus making a comprehensive and objective assessment of the global schistosomiasis epidemic." Zhou Xiaonong, director of the Institute of Parasitic Diseases Prevention and Control of China Center for Disease Control and Prevention, said: "This study focuses on the current needs of schistosomiasis prevention and control in China, which has played a positive role in promoting the accuracy of schistosomiasis screening and the sensitivity of monitoring, and is a model for relying on scientific research to solve key technical problems in prevention and control."
Professor Pan led the team of "Basic Research on Malaria and Schistosomiasis Prevention and Control", including researchers from Tongji University Medical College, Jiangxi Institute of Parasitic Disease Prevention and Control, Suzhou University Medical College, Department of Thermal Health of the Second Military Medical University, etc., and screened the marker molecules for schistosomiasis diagnosis from the whole genome level. The team first established a technical platform for Qualcomm screening of fusion secreted proteins, and then screened marker molecules with diagnostic value from the genome on a large scale, and identified a marker molecule with diagnostic value (namely SjSP- 13) from more than 200 secreted proteins of Schistosoma japonicum, and its diagnostic sensitivity was 6 times higher than that of traditional methods.
Professor Pan said that the overall strategy of schistosomiasis control in China is a comprehensive control strategy based on controlling the source of infection. The important way to control the source of infection is to find the infected people in time and accurately, and to treat all the infected people effectively. Because the epidemic characteristics of schistosomiasis are mainly low-level infection, and the diagnosis of low-level infection requires high-sensitivity technology, the discovery of SjSP- 13 diagnostic molecules has solved the fundamental problem of insufficient sensitivity of existing diagnostic technologies. The application of this molecule will certainly provide important technical support for the implementation of the overall prevention and control strategy of schistosomiasis, and will have a positive impact on the prevention and control and even elimination of schistosomiasis in China.